Mankind Pharma shares gained 2.10% to trade at Rs 2,482.80 in Wednesday's session. At 10:21 am, the stock showcased positive movement on the NIFTY MIDCAP 150.
On the financial front, the company's standalone annual revenue has shown consistent growth over the past five years. In March 2021, the revenue stood at Rs 5,529 Crore, which increased to Rs 7,257 Crore in March 2022, Rs 8,127 Crore in March 2023, and further to Rs 9,264 Crore in March 2024. The latest figure for March 2025 is Rs 9,497 Crore.
The net profit also reflects this upward trajectory. The net profit was Rs 1,084 Crore in March 2021, rising to Rs 1,335 Crore in March 2022, Rs 1,248 Crore in March 2023, Rs 1,823 Crore in March 2024, and Rs 1,945 Crore in March 2025.
Here is a detailed look at the financial performance of Mankind Pharma:
| Financial Year | Sales (Rs Crore) | Other Income (Rs Crore) | Total Income (Rs Crore) | Total Expenditure (Rs Crore) | EBIT (Rs Crore) | Interest (Rs Crore) | Tax (Rs Crore) | Net Profit (Rs Crore) |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | Rs 9,497 | Rs 493 | Rs 9,991 | Rs 7,313 | Rs 2,738 | Rs 371 | Rs 421 | Rs 1,945 |
| Mar 2024 | Rs 9,264 | Rs 266 | Rs 9,531 | Rs 7,257 | Rs 2,274 | Rs 14 | Rs 436 | Rs 1,823 |
| Mar 2023 | Rs 8,127 | Rs 162 | Rs 8,289 | Rs 6,699 | Rs 1,590 | Rs 27 | Rs 314 | Rs 1,248 |
| Mar 2022 | Rs 7,257 | Rs 162 | Rs 7,419 | Rs 5,578 | Rs 1,841 | Rs 43 | Rs 462 | Rs 1,335 |
| Mar 2021 | Rs 5,529 | Rs 148 | Rs 5,677 | Rs 4,229 | Rs 1,448 | Rs 7 | Rs 355 | Rs 1,084 |
The quarterly financial performance provides additional insights. The sales for the quarter ending March 2024 were Rs 2,152 Crore, which increased to Rs 2,403 Crore by June 2024, Rs 2,529 Crore by September 2024, and then slightly decreased to Rs 2,396 Crore by December 2024. The most recent quarter, ending March 2025, shows sales of Rs 2,126 Crore.
The net profit figures for the same period were Rs 454 Crore, Rs 513 Crore, Rs 634 Crore, Rs 416 Crore, and Rs 382 Crore, respectively.
Here is a summary of the quarterly income statement:
| Quarter | Sales (Rs Crore) | Other Income (Rs Crore) | Total Income (Rs Crore) | Total Expenditure (Rs Crore) | EBIT (Rs Crore) | Interest (Rs Crore) | Tax (Rs Crore) | Net Profit (Rs Crore) |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | Rs 2,126 | Rs 219 | Rs 2,345 | Rs 1,754 | Rs 591 | Rs 162 | Rs 46 | Rs 382 |
| Dec 2024 | Rs 2,396 | Rs 69 | Rs 2,466 | Rs 1,742 | Rs 723 | Rs 199 | Rs 107 | Rs 416 |
| Sep 2024 | Rs 2,529 | Rs 105 | Rs 2,635 | Rs 1,863 | Rs 804 | Rs 1 | Rs 168 | Rs 634 |
| Jun 2024 | Rs 2,403 | Rs 94 | Rs 2,498 | Rs 1,914 | Rs 612 | Rs 6 | Rs 93 | Rs 513 |
| Mar 2024 | Rs 2,152 | Rs 83 | Rs 2,236 | Rs 1,687 | Rs 548 | Rs 4 | Rs 90 | Rs 454 |
As per the ratios, the Basic EPS (Rs.) stood at 48.16 in March 2025 compared to 45.52 in March 2024. The diluted EPS (Rs.) was 48.07 in March 2025 compared to 45.45 in March 2024. The debt to equity ratio is 0.50 as of March 2025.
Mankind Pharma has shown a positive movement of 2.10% in today's trading session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
